Henan Taloph Pharmaceutical Stock Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE0000010L8
CNY
8.58
0.54 (6.72%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
1,930.30
2,059.98
1,952.27
1,596.62
1,409.68
1,303.48
1,183.89
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,930.30
2,059.98
1,952.27
1,596.62
1,409.68
1,303.48
1,183.89
Raw Material Cost
1,475.00
1,531.34
1,511.47
1,158.70
1,062.85
853.05
836.93
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
285.37
305.80
291.69
229.96
172.27
193.76
157.91
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
61.23
55.70
65.77
87.11
75.05
69.12
58.46
Selling and Distribution Expenses
293.19
323.15
337.21
260.96
213.07
297.53
231.93
Other Expenses
-25.47
-24.39
-24.93
-26.72
-19.06
-21.05
-16.64
Total Expenditure (Excl Depreciation)
1,860.05
1,972.12
1,956.87
1,469.56
1,332.63
1,202.98
1,118.79
Operating Profit (PBDIT) excl Other Income
70.19999999999999
87.89999999999999
-4.6000000000000005
127.10000000000001
77.1
100.5
65.1
Other Income
14.75
22.84
17.97
15.37
27.70
19.55
9.03
Operating Profit (PBDIT)
161.45
183.22
77.47
166.81
147.18
160.52
128.75
Interest
61.23
55.70
65.77
87.11
75.05
69.12
58.46
Exceptional Items
7.94
-0.53
-20.55
-11.78
2.38
-0.45
-129.43
Gross Profit (PBDT)
455.29
528.64
440.79
437.92
346.83
450.43
346.96
Depreciation
73.21
75.69
67.93
60.50
46.42
43.12
56.89
Profit Before Tax
34.94
51.29
-76.78
7.42
28.10
47.84
-116.03
Tax
-18.42
-1.87
-7.09
0.67
1.64
4.75
0.12
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
50.53
43.56
-72.20
6.00
29.24
44.41
-115.32
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
50.53
43.56
-72.20
6.00
29.24
44.41
-115.32
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
2.97
1.27
-3.56
0.78
-1.65
-1.85
-0.14
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
53.50
44.83
-75.76
6.78
27.60
42.57
-115.46
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
1,574.73
1,578.49
1,570.42
1,660.51
1,453.42
1,375.00
1,388.81
Earnings per share (EPS)
0.09
0.08
-0.13
0.01
0.05
0.08
-0.2
Diluted Earnings per share
0.09
0.08
-0.13
0.01
0.05
0.08
-0.2
Operating Profit Margin (Excl OI)
3.81%
4.11%
-0.43%
5.7%
5.18%
7.51%
5.31%
Gross Profit Margin
5.6%
6.16%
-0.45%
4.25%
5.29%
6.98%
-5.0%
PAT Margin
2.62%
2.11%
-3.7%
0.38%
2.07%
3.41%
-9.74%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is -6.30% vs 5.52% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 19.42% vs 159.10% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is -8.54% vs 169.58% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is 9.87% vs -15.35% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has fallen from Dec 2023

Compare Annual Results Of Henan Taloph Pharmaceutical Stock Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
1,930.30
0
1,930.30
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,930.30
0
1,930.30
Raw Material Cost
1,475.00
0
1,475.00
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
285.37
0
285.37
Power Cost
0
0
0.00
Manufacturing Expenses
61.23
0
61.23
Selling and Distribution Expenses
293.19
0
293.19
Other Expenses
-25.47
0.00
-25.47
Total Expenditure (Excl Depreciation)
1,860.05
0
1,860.05
Operating Profit (PBDIT) excl Other Income
70.25
0.00
70.25
Other Income
14.75
0
14.75
Operating Profit (PBDIT)
161.45
0
161.45
Interest
61.23
0
61.23
Exceptional Items
7.94
0
7.94
Gross Profit (PBDT)
455.29
0
455.29
Depreciation
73.21
0
73.21
Profit Before Tax
34.94
0
34.94
Tax
-18.42
0
-18.42
Provisions and contingencies
0
0
0.00
Profit After Tax
50.53
0
50.53
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
50.53
0
50.53
Share in Profit of Associates
0
0
0.00
Minority Interest
2.97
0
2.97
Other related items
0.00
0.00
0.00
Consolidated Net Profit
53.50
0
53.50
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
1,574.73
0
1,574.73
Earnings per share (EPS)
0.09
0
0.09
Diluted Earnings per share
0.09
0
0.09
Operating Profit Margin (Excl OI)
3.81%
0%
0.00
3.81%
Gross Profit Margin
5.60%
0%
0.00
5.60%
PAT Margin
2.62%
0%
0.00
2.62%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 193.03 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -6.30% vs 5.52% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 5.35 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 19.42% vs 159.10% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 14.67 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -8.54% vs 169.58% in Dec 2023

Annual - Interest
Interest 6.12 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 9.87% vs -15.35% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 3.81%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has fallen from Dec 2023